Finding Hope in Treatment: New Developments in MPN Research 2023

Anti-Mutant CALR Therapy & Key MPN Insights from ASH 2022 – Dr. Srdan Verstovsek

🩸 Could a new anti-mutant CALR monoclonal antibody lead to a molecular response in Myelofibrosis (MF) and Essential Thrombocythemia (ET)?

In this compelling discussion, MPN expert Dr. Srdan Verstovsek shares insights from ASH 2022, covering exciting new treatment approaches and answering critical questions for MPN patients.

📌 Key Topics Covered:

A new anti-mutant CALR monoclonal antibody and its potential impact on MF and ET
Top highlights from the ASH 2022 conference and what treatments may be available soon
Is fibrosis a reliable marker for Myelofibrosis progression?
Are all MPN symptoms disease-related, or could there be other causes?
🎙️ Patients Are Asking – Episode 3 from ASH 2022

📢 Stay informed about the latest breakthroughs in MPN treatment and research!

🌐 For more information, visit:
🔗 PV Reporter - https://www.pvreporter.com/
🔗 MPN Cancer Connection - https://mpncancerconnection.org/

📢 Copyright Notice: This video is the property of PV Reporter and MPN Cancer Connection. Unauthorized use, reproduction, or distribution without permission is prohibited.

👍 If you found this discussion helpful, please like, subscribe, and share!

#MPN #Myelofibrosis #EssentialThrombocythemia #BloodCancer #MPNSpecialist #CALRMutation #MPNResearch #ASH2022 #PVReporter #PatientAdvocacy